Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,958 total articles
United Parks & Resorts (PRKS) has been punished for attendance hiccups and earnings misses, but the underlying cash generation and valuation multiples argue for a long trade. I outline an actionable plan with entry, stop and target, explain the fundamental backdrop, list catalysts, and lay out the risks that could derail the thesis.
Precision Drilling trades at a sub-1 PB, sits near oversold technicals (RSI ~31.6) and has a compact market cap of roughly $1.0B. I plan a long trade at the current price with a $97 target over 180 trading days and a $72 stop — a trade that balances upside from a potential re-rating and operational improvement against clear cyclical and execution r…
Precigen is showing the first signs of commercial scale after FDA approval of PAPZIMEOS: $21.6M in net product revenue in the first full quarter, permanent J-code reimbursement, broad payer coverage and a path to cash-flow break-even by year-end. The stock carries lofty valuation multiples, heavy short interest and an overbought technical reading, …
KULR Technology Group ($KULR) remains a compelling takeover candidate based on proprietary carbon-fiber thermal products, recent strategic collaborations, constrained market value (EV ~$170M), and a sizeable short interest that can amplify moves. This trade idea lays out an actionable long with entry, stop, and target, plus catalysts and risks to w…
MoonLake Immunotherapeutics is a clinical-stage biotech with a single major value driver: sonelokimab. With Phase 3 Week-40 results showing durable responses and management targeting a BLA submission in H2 2026, MLTX offers an asymmetric risk/reward for a disciplined long trade. The company has meaningful cash per share and an upcoming regulatory c…
Spyre Therapeutics has pivoted from single-agent binary risk toward a deliberately engineered combination strategy. Positive Phase 2 SKYLINE Part A results for SPY001, an upsized $403M financing, and a deepening commercial bench justify a mid-term long trade that targets upside toward the 52-week range while respecting biotech volatility with a tig…
Tesla's valuation still embeds moonshot expectations, but two large initiatives - Full Self-Driving/robotaxi economics and accelerating energy storage sales - are moving from theory to measurable revenue vectors. With a $1.44T market cap, $7B of free cash flow and stretched multiples, this trade targets a measured long exposure with a mid-term hori…
Sandisk's meteoric rally has grabbed headlines, but it feels closer to a speculative blowoff than a sustainable re-rating. Western Digital offers a more measured exposure to the AI-driven storage boom: strong cash generation, healthy margins, and a balance sheet that can handle normalizing memory cycles. This trade idea buys the recent WDC weakness…
Western Midstream (WES) offers an industry-leading yield (about 8.6%) backed by ~$1.34B in free cash flow, a midstream asset base tied to production growth, and valuation support near the midpoint of its 52-week range. This trade plan targets a move back to $48 while keeping a protective stop below $38.50.
Uber’s core marketplace is accelerating: gross bookings are up 25%, revenue climbed to $13.2B in the most recent quarter, and free cash flow sits near $9.1B. The market is fretting over an AI-driven capex and R&D ramp, but those investments sit on top of a highly cash-generative platform with attractive multiples. This trade idea lays out an action…
<p>Microsoft reportedly shed about $1.3 trillion in market value from its prior peak. We view a sizeable portion of that drawdown as temporary price action tied to sentiment and short-term risk-off positioning rather than a permanent impairment of fundamentals. This trade idea upgrades Microsoft to a buy and lays out a tactical long with clear entr…
Pfizer offers a rare combination today: a double-digit-ish dividend yield (above 7%), healthy free cash flow ($9.49B) and an inexpensive EV/EBITDA (~8.3x). Those attributes make a disciplined long trade attractive even as the company navigates a patent cliff and pipeline execution risk. This idea lays out an entry at $24.10, a $28 target and a $21.…
Exail Technologies is a small, specialized defense and robotics company with attractive strategic assets but thin liquidity and takeover dynamics that can cap upside. We lay out a mid-term long trade with a clearly defined stop and target, alongside the catalysts and the takeover risk that should keep position sizes conservative.
Ford's recent price swing tied to AI/energy headlines created an entry window. At $14.39, the stock trades cheaply by several valuation metrics, generates roughly $9.55B of free cash flow, and yields about 4.25% after the $0.15 quarterly dividend. This trade targets a mid-term rebound to $16.50 while limiting downside to $13.50. The thesis rests on…
Rheinmetall’s share-price weakness after recent headlines looks overdone relative to order backlog, cash generation potential, and medium-term margin normalisation. We upgrade to Strong Buy and lay out an actionable trade: entry $180.00, target $230.00, stop $150.00.
Fabrinet (FN) plunged after a Q3 beat but fundamentals—strong profitability metrics, a solid revenue run-rate and improving datacenter optics demand—suggest the sell-off is an opportunity. A capacity build-out (management commentary and industry signals) should drive revenue leverage into FY27. Trade plan: enter on weakness, size for a recovery int…
NVR has the operational profile of a conservative, cash-generative homebuilder and is trading below its 52-week high after a cyclical pullback. With ROE above 35%, FCF near $1.23B, and an asset-light land model, the company can weather high mortgage rates better than many peers. This trade targets a recovery toward $8,000 over the next 180 trading …
SkyWest trades at about a single-digit P/E and an EV/EBITDA below 7 while producing >$300M in free cash flow. The stock looks materially cheap versus its earnings power and franchise exposure to mainline capacity. Initiate a long position with a clearly defined entry, stop and target and a 180-trading-day time horizon.
We upgrade Amazon to a buy and recommend a swing trade entry at current levels. Macroeconomic improvement and accelerating AI monetization — including potential external sales of Trainium chips — support upside to $265 over the next ~45 trading days. Valuation, healthy profitability metrics, and a manageable balance sheet provide a buffer despite n…
Backblaze (BLZE) has shed its dormant label and is seeing a fresh re-rate driven by AI customer growth, improving margins and guidance toward positive adjusted free cash flow in H2 2026. The technical breakout and low days-to-cover shorts add momentum, but legal questions and high valuation metrics require disciplined risk management. We recommend …
Five Star Bancorp (FSBC) is a compact Northern California regional bank with above-average returns, a modest valuation at current earnings, and a concentrated CRE and agribusiness lending strategy that is being scaled carefully. We propose a long trade with entry at $47.92, target $60.00 and stop loss $42.00 over a long-term (180 trading days) hori…
Amazon is investing aggressively in AI infrastructure across AWS, custom silicon, and logistics. These investments temporarily pressure free cash flow but reinforce a competitive moat that can drive higher AWS margins, a new AI-chip revenue stream, and stronger ad monetization. The trade: initiate a long on AMZN at $231.28 with a $270 target over 1…
ANI Pharmaceuticals is growing into a rare-disease specialty story while still generating generics cash flow. The company reported record 2025 revenue of $883.4M (up 43.8% YoY) and is guiding to >$1B in 2026. At a market cap near $1.93B and a P/E ~21, the stock trades like a generics mid-cap despite rare-disease growth driving margin expansion and …
Veeva Systems (VEEV) remains one of the highest-quality vertical SaaS franchises: recurring subscription growth, strong free cash flow, and a pristine balance sheet. Recent beats and raised FY2027 guidance validate the business, but the stock has been volatile and still trades well off its 52-week peak. This trade idea offers a structured long with…
Cognition Therapeutics (CGTX) has tangible clinical progress and a clearer path to Phase 3 for CT1812 (zervimesine), supported by a $30M registered direct offering last year. At a market cap near $102M and a current price of $1.145, the stock offers upside if Phase 3 plans and regulatory interactions check boxes; downside is dominated by funding ne…
